3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Dacarbazine
25
Nivolumab
24
pembrolizumab
19
Ipilimumab
18
Interferon-alpha
10
trametinib
8
Vemurafenib
8
dabrafenib
7
aldesleukin
7
Temozolomide
7
Introns
7
Interferon alpha-2
6
Interleukin-2
5
Cisplatin
5
Chemotherapy, Adjuvant
5
talimogene laherparepvec
4
cemiplimab
4
binimetinib
4
Radiotherapy
4
Paclitaxel
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
sargramostim
3
encorafenib
3
cobimetinib
3
Vinblastine
3
Surgical Procedures, Operative
3
Specimen Handling
3
Sodium Chloride
3
Radiosurgery
3
Opdualag
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Melanoma
×
Technetium-99
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled